Jeong SH, Yoo MW, Son YG, et al. - Researchers sought to determine the satisfactory minimum number of adjuvant chemotherapy (AC) cycles needed to attain an oncologic benefit for gastric cancer. They analyzed data from 925 patients who underwent curative radical gastrectomy and then were given AC for pathologic stage 2 or 3 gastric cancer at 27 institutions in South Korea from January 2012 to December 2013. Of these patients, 661 (71.5%) completed 8 cycles of AC and 264 patients (28.5%) did not. Outcomes suggest that 6 or 7 AC cycles results in disease-free survival (DFS) similar to that noted for 8 AC cycles as an adjuvant treatment for gastric cancer. The mean DFS of patients who completed 6 AC cycles (72.4 months) and those who completed 7 AC cycles (63.7 months) did not differ significantly vs the mean DFS of patients who completed 8 AC cycles (69.3 months). However, the mean DFS of the patients who completed 5 AC cycles (48.2 months) and those who completed 1–4 AC cycles (62.9 months) was significantly lower than the DFS of those who completed 8 AC cycles.